Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583563 | 1.00 | HTT (0.58) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| Hydrochloric Acid SCHEMBL11278994 | 0.98 | HTT (0.57) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL561284 | 0.93 | HTT (0.64) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL8413418 | 0.92 | HTT (0.51) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| Methyl 3,5-Dinitrobenzoate SCHEMBL418416 | 0.89 | SMN1; SMN2 (0.60) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL8762477 | 0.88 | HTT (0.59) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL16960801 | 0.86 | HTT (0.58) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL4731202 | 0.86 | HTT (0.58) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL232779 | 0.85 | TP53 (0.64) | SMN1; SMN2POLBMEN1KMT2AMAPT | |
| SCHEMBL30917332 | 0.85 | SMN1; SMN2 (0.57) | HTTSMN1; SMN2GAAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 429 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344743-B | High-viscosity modified asphalt and preparation method thereof | 南京航空航天大学 | 2024-11-26 | — | — | CN | claimed |
| CN-118344743-A | High-viscosity modified asphalt and preparation method thereof | 南京航空航天大学 | 2024-07-16 | — | — | CN | claimed |
| CN-115521228-B | BChE and HDAC double-target inhibitor and preparation method and application thereof | 中国药科大学 | 2023-08-22 | — | — | CN | claimed |
| CN-115521228-A | BChE and HDAC double-target inhibitor and preparation method and application thereof | 中国药科大学 | 2022-12-27 | — | — | CN | claimed |
| CN-112851537-A | Contrast agent iopromide intermediate and preparation method and application thereof | 施一新 | 2021-05-28 | — | — | CN | claimed |
| EP-4172139-B1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | GE HEALTHCARE AS (NO) | 2025-09-24 | — | — | EP | disclosed |
| US-20250115634-A1 | LIGAND, METHOD FOR PREPARING SAME, AND USE THEREOF | LNCTAC CO., LTD. (CN) | 2025-04-10 | — | — | US | disclosed |
| WO-2025045826-A1 | COMPOUNDS FOR ACTIVATION OF FGFR1 SIGNALING | THE CULTIVATED B. GMBH (DE) | 2025-03-06 | — | — | WO | disclosed |
| CN-116478129-B | Quinoline compound and use thereof | 深圳默元生物科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240425445-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & CO (US) | 2024-12-26 | — | — | US | disclosed |
| CN-118344743-B | High-viscosity modified asphalt and preparation method thereof | 南京航空航天大学 | 2024-11-26 | — | — | CN | disclosed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-4364921-A | RADIOPACITY | SCHERING, AKTIENGESELLSCHAFT (DE) | 1982-12-21 | — | — | US | disclosed |
| EP-0015867-B1 | DIAMIDES OF TRIIODO-ISOPHTHALIC ACIDS, THEIR PREPARATION AND X-RAY CONTRAST AGENTS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-05-19 | — | — | EP | disclosed |
| EP-0015867-A1 | Diamides of triiodo-isophthalic acids, their preparation and X-ray contrast agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-09-17 | — | — | EP | disclosed |
| US-4138589-A | CHEMICAL INTERMEDIATES FOR COMPOUNDS USED AS X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4132731-A | X-RAY CONTRAST AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-01-02 | — | — | US | disclosed |
| US-4069250-A | X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1978-01-17 | — | — | US | disclosed |
| US-4066743-A | TRIIODOBENZOIC ACID DERIVATIVES | MALLINCKRODT, INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-3995044-A | Pyridine carboxylic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425445-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | PTAR1, TIPRL, TCOF1 | HTT 466/4885SMN1; SMN2 2156/4885GAA 1590/4885 |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HTT 1201/4885SMN1; SMN2 2963/4885GAA 7/4885 |
| US-20250115634-A1 | LIGAND, METHOD FOR PREPARING SAME, AND USE THEREOF | SIGLEC7, ASGR1, ADGRF1 | HTT 4745/4885SMN1; SMN2 4428/4885GAA 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.